AMAM — Ambrx Biopharma Income Statement
0.000.00%
Last trade - 00:00- $1.76bn
- $1.54bn
- $7.40m
Annual income statement for Ambrx Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 10.3 | 13.7 | 7.46 | 7.4 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 32.8 | 26.8 | 71.9 | 83.8 |
| Operating Profit | -22.5 | -13.1 | -64.4 | -76.4 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -22.3 | -17.8 | -68.3 | -76.1 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -22.3 | -17.8 | -68.3 | -78 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -20.1 | -16.5 | -68.1 | -78 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -20.1 | -16.5 | -68.1 | -78 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.076 | -0.063 | -0.251 | -0.265 |